Developing endpoints for the cardiac burden in myotonic dystrophy type 1: A workshop report
Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1567-1579
DOI: 10.1177/22143602261433484 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 07.04.2026. Verfasst von Julia M Hartman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond, VA, USA. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Heart Diseases, Endpoint Determination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Cardiac disease is a well-established manifestation of myotonic dystrophy type 1 (DM1), characterized by progressive cardiac conduction slowing with increased risk of atrial and ventricular arrhythmias, heart block, and sudden cardiac death. Multiple disease modifying therapies are in clinical trials for DM1 and show promise in improving skeletal muscle weakness and myotonia. Testing the effects of these medicines, or others, in the heart is of critical importance, but requires identification of endpoints of cardiac function that accurately reflect the state of DM1 cardiac disease. To better define cardiac endpoints, the Myotonic Dystrophy Clinical Research Network (DMCRN) and the Myotonic Dystrophy Foundation (MDF) convened a workshop entitled ‘‘Cardiac Endpoint Workshop’’ in May 2025 at the Myotonic Dystrophy Foundation International Conference. Here, we summarize the discussion at the workshop and perform secondary analysis of cardiac outcomes in the published literature to evaluate cardiac endpoints for clinical impact and trial feasibility. This analysis demonstrates that major cardiac events are too infrequent (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virginia Commonwealth University, Richmond, VA, USA.
- Ralph H. Johnson VA Medical Center and Medical University of South Carolina, Charleston, SC, USA.
- Baylor College of Medicine, Houston, TX, USA.
- Roseman University of Health Sciences, South Jordan, UT, USA.
ORCID-Profile: Samuel Carrell, Jordana Kron, Jennifer Jordan
Förderung
- NICHD NIH HHS
- NINDS NIH HHS
- NIAMS NIH HHS
- NHLBI NIH HHS
- FDA HHS
- Avidity Biosciences
- Sanofi Genzyme
- Takeda Medical Research Foundation
Zitieren
APA
Hartman, J. M., Carrell, S., Groh, W. J., Cooper, T. A., Kron, J., Hundley, G., Jordan, J., Ladd, A., Hung, M., Johnson, N. E., & Myotonic Dystrophy Clinical Research Network (DMCRN) and the Myotonic Dystrophy Foundation (MDF) (2026). Developing endpoints for the cardiac burden in myotonic dystrophy type 1: A workshop report. Journal of Neuromuscular Diseases, 13(6), 1567-1579. https://doi.org/10.1177/22143602261433484
Vancouver
Hartman JM, Carrell S, Groh WJ, Cooper TA, Kron J, Hundley G, et al. Developing endpoints for the cardiac burden in myotonic dystrophy type 1: A workshop report. Journal of Neuromuscular Diseases. 2026;13(6):1567-1579. doi:10.1177/22143602261433484
BibTeX
@article{Hartman2026,
author = {Hartman, Julia M and Carrell, Samuel and Groh, William J and Cooper, Thomas A and Kron, Jordana and Hundley, Greg and Jordan, Jennifer and Ladd, Amy and Hung, Man and Johnson, Nicholas E and Myotonic Dystrophy Clinical Research Network (DMCRN) and the Myotonic Dystrophy Foundation (MDF), Myotonic Dystrophy Clinical Research Network (DMCRN) and the Myotonic Dystrophy Foundation (MDF)},
title = {Developing endpoints for the cardiac burden in myotonic dystrophy type 1: A workshop report},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
volume = {13},
number = {6},
pages = {1567--1579},
doi = {10.1177/22143602261433484}
}
EUVIMED